Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int Immunopharmacol. 2009 Mar;9(3):340-6. doi: 10.1016/j.intimp.2008.12.012. Epub 2009 Jan 20.

Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro.

Author information

  • 1Department of Immunology, University of Connecticut Health Center 263 Farmington Ave, MC1319Farmington, CT 06030, USA. esecor@uchc.edu

Abstract

Bromelain (Br), an extract from pineapple stem with cysteine protease activity, exerts anti-inflammatory effects in a number of inflammatory models. We have previously shown that Br treatment decreased activated CD4(+) T cells and has a therapeutic role in an ovalbumin-induced murine model of allergic airway disease. The current study was designed to determine the effect of Br on CD4(+) T cell activation, specifically the expression of CD25 in vitro. CD25 is up regulated upon T cell activation, found as a soluble fraction (sCD25) and is a therapeutic target in inflammation, autoimmunity and allergy. Br treatment of anti-CD3 stimulated CD4(+) T cells reduced CD25 expression in a dose and time dependent manner. This reduction of CD25 was dependent on the proteolytic action of Br as the addition of E64 (a cysteine protease inhibitor) abrogated this response. The concentration of sCD25 was increased in supernatants of Br treated activated CD4(+) T cells as compared to control cells, suggesting that Br proteolytically cleaved cell-surface CD25. This novel mechanism of action identifies how Br may exert its therapeutic benefits in inflammatory conditions.

PMID:
19162239
[PubMed - indexed for MEDLINE]
PMCID:
PMC2662479
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk